Virentis Bio develops first-in-class, broad-spectrum small-molecule antivirals to prevent the next alphavirus epidemic, built before outbreak conditions create barriers to access.
Deliver first-in-class, broad-spectrum antivirals to prevent the next alphavirus epidemic.
There are no approved therapeutics for any alphavirus, including chikungunya, a rapidly growing global health and economic threat.
Three antiviral candidates, each targeting a distinct viral factor and broadly effective across multiple alphaviruses.
Advance our lead compounds through Phase I: the first clinical-stage antiviral against endemic, epidemic, and weaponized alphaviruses.
Alphaviruses are mosquito-borne, fast-spreading, and have no approved therapy. Each carries market potential on the order of chikungunya, and our chemistry is built to address all of them.
Crippling joint disease, now spreading into the US & Europe.
Affects both humans and horses; a known bioterror agent.
Emerging from the Amazon basin into cities worldwide.
CHIKV causes disease in more than 70% of infected individuals, with an acute phase severe enough to bedridden most patients, and a chronic phase that can last for years.
Sudden high fever, headache, fatigue, rash, and nausea.
Multi-joint arthritis with an average pain score of 8.3 / 10; over 90% of patients bedridden for more than 7 days.
40 to 60% remain symptomatic at 3 months; ~30% at 18 months; ~10% beyond 2 years.
Each Virentis compound is a first-in-class antiviral that targets a unique viral enzyme, together delivering potency against chikungunya and breadth across the entire alphavirus genus.
Each compound targets a unique viral enzyme.
Potent antiviral activity against chikungunya and across the alphavirus genus.
Lead and both backups prevent replication and disease in preclinical CHIKV animal models.
Three distinct targets de-risk technical failure and enable follow-on combination therapy.
Expanded mosquito range across the US and EU makes a CHIKV epidemic highly likely within the next two years, and the treatable population is growing.
Positive pre-IND feedback for our lead asset, VB-101, provides regulatory clarity for all assets through Phase I.
CHIKV antivirals are eligible for Fast Track, Orphan Drug Designation, and Priority Review.
We work with early-stage investors, government and global-health funders, pharma partners, and the scientific community. Tell us how you’d like to engage.
